BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has received an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price objective among […]
Forget about the Magnificent Seven and AI. The stocks that did the absolute best during the year were tied to biotech and crypto along with one car-related.
Forget about the Magnificent Seven and AI. The stocks that did the absolute best during the year were tied to biotech and crypto along with one car-related.
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Randal W. Scott sold 2,000 shares of BridgeBio Pharma stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $40.00, for a total value of $80,000.00. Following the completion of the transaction, the director now owns 9,000 shares of […]
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $37.03 and last traded at $36.34, with a volume of 530472 shares traded. The stock had previously closed at $35.91. Analyst Upgrades and Downgrades BBIO has been the topic of […]